Royalty Pharma (RPRX) Revenue & Revenue Breakdown
Royalty Pharma Revenue Highlights
Latest Revenue (Y)
$2.35B
Latest Revenue (Q)
$567.98M
Main Segment (Y)
Financial Royalty Assets
Royalty Pharma Revenue by Period
Royalty Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.35B | 5.24% |
| 2022-12-31 | $2.24B | -2.28% |
| 2021-12-31 | $2.29B | 7.89% |
| 2020-12-31 | $2.12B | 16.96% |
| 2019-12-31 | $1.81B | 1.08% |
| 2018-12-31 | $1.79B | 12.33% |
| 2017-12-31 | $1.60B | - |
Royalty Pharma generated $2.35B in revenue during NA 2023, up 5.24% compared to the previous quarter, and up 131.18% compared to the same period a year ago.
Royalty Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $567.98M | -4.70% |
| 2023-12-31 | $596.00M | 11.13% |
| 2023-09-30 | $536.31M | -0.35% |
| 2023-06-30 | $538.20M | -21.31% |
| 2023-03-31 | $683.97M | 20.90% |
| 2022-12-31 | $565.75M | -1.35% |
| 2022-09-30 | $573.46M | 7.00% |
| 2022-06-30 | $535.96M | -4.64% |
| 2022-03-31 | $562.05M | -2.37% |
| 2021-12-31 | $575.70M | -1.72% |
| 2021-09-30 | $585.77M | 5.55% |
| 2021-06-30 | $554.96M | -3.15% |
| 2021-03-31 | $573.03M | 0.35% |
| 2020-12-31 | $571.00M | 5.94% |
| 2020-09-30 | $539.00M | 5.49% |
| 2020-06-30 | $510.93M | 2.01% |
| 2020-03-31 | $500.88M | 9.49% |
| 2019-12-31 | $457.49M | -1.46% |
| 2019-09-30 | $464.28M | 1.46% |
| 2019-06-30 | $457.61M | 5.23% |
| 2019-03-31 | $434.88M | - |
Royalty Pharma generated $567.98M in revenue during Q1 2024, up -4.70% compared to the previous quarter, and up 100.39% compared to the same period a year ago.
Royalty Pharma Revenue Breakdown
Royalty Pharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Intangible Royalty Assets | $835.00K | $37.48M | $171.25M | $143.38M |
| Financial Royalty Assets | $2.20B | $2.13B | $2.07B | $1.96B |
| Royalty Income, Other | $155.97M | $74.64M | $53.13M | $19.00M |
Royalty Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 23: Financial Royalty Assets (93.34%), Royalty Income, Other (6.62%), and Intangible Royalty Assets (0.04%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty Income, Other | $26.43M | $72.77M | $27.40M | $36.66M | $19.14M | $18.92M | $20.71M | $18.07M | $16.94M | $17.83M | $16.54M | $11.42M | $7.34M | $7.30M | $5.33M | $3.31M |
| Financial Royalty Assets | $541.55M | $523.07M | $508.66M | $501.35M | $664.69M | $546.54M | $551.68M | $515.35M | $511.52M | $526.21M | $505.83M | $503.41M | $529.63M | $524.44M | $498.51M | $474.18M |
| Intangible Royalty Assets | - | $238.00K | $252.00K | $202.00K | $143.00K | $288.00K | $1.07M | $2.54M | $33.59M | $31.65M | $63.41M | $40.13M | $36.06M | $40.40M | $34.55M | $33.45M |
Royalty Pharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Financial Royalty Assets (95.35%), and Royalty Income, Other (4.65%).
Royalty Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BGNE | BeiGene | $2.46B | $929.17M |
| RPRX | Royalty Pharma | $2.35B | $567.98M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| DNA | Ginkgo Bioworks | $251.46M | $56.21M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| ADPT | Adaptive Bio | $170.28M | $43.19M |
| CVAC | CureVac | $52.70M | $12.37M |
| VECT | VectivBio | $27.34M | $676.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| IOVA | Iovance Biotherapeutics | $1.19M | $31.11M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| KNTE | Kinnate Biopharma | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| PRME | Prime Medicine | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| OCEA | Ocean Biomedical | - | - |
| AKRO | Akero Therapeutics | - | - |
| RPHM | Reneo Pharmaceuticals | - | - |
RPRX Revenue FAQ
What is Royalty Pharma’s yearly revenue?
Royalty Pharma's yearly revenue for 2023 was $2.35B, representing an increase of 5.24% compared to 2022. The company's yearly revenue for 2022 was $2.24B, representing a decrease of -2.28% compared to 2021. RPRX's yearly revenue for 2021 was $2.29B, representing an increase of 7.89% compared to 2020.
What is Royalty Pharma’s quarterly revenue?
Royalty Pharma's quarterly revenue for Q1 2024 was $567.98M, a -4.70% decrease from the previous quarter (Q4 2023), and a -16.96% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $596M, a 11.13% increase from the previous quarter (Q3 2023), and a 5.35% increase year-over-year (Q4 2022). RPRX's quarterly revenue for Q3 2023 was $536.31M, a -0.35% decrease from the previous quarter (Q2 2023), and a -6.48% decrease year-over-year (Q3 2022).
What is Royalty Pharma’s revenue growth rate?
Royalty Pharma's revenue growth rate for the last 3 years (2021-2023) was 2.84%, and for the last 5 years (2019-2023) was 29.78%.
What are Royalty Pharma’s revenue streams?
Royalty Pharma's revenue streams in c 23 are Intangible Royalty Assets, Financial Royalty Assets, and Royalty Income, Other. Intangible Royalty Assets generated $835K in revenue, accounting 0.04% of the company's total revenue, down -97.77% year-over-year. Financial Royalty Assets generated $2.2B in revenue, accounting 93.34% of the company's total revenue, up 3.42% year-over-year. Royalty Income, Other generated $155.96M in revenue, accounting 6.62% of the company's total revenue, up 108.97% year-over-year.
What is Royalty Pharma’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Royalty Pharma was Financial Royalty Assets. This segment made a revenue of $2.2B, representing 93.34% of the company's total revenue.